This paper provides a detailed protocol and translational considerations for manufacturing third-generation lentiviral vectors for preclinical and clinical gene therapy applications.
Answers are grounded in this paper and cite their sources.
Supports preclinical lentiviral production; leaves open GMP translation for clinical gene therapy trials.
Lentiviral vectors are used in laboratories around the world for in vivo and ex vivo delivery of gene therapies, and increasingly clinical investigation as well as preclinical applications. The third-generation lentiviral vector system has many advantages, including high packaging capacity, stable gene expression in both dividing and post-mitotic cells, and low immunogenicity in the recipient organism. Yet, the manufacture of these vectors is challenging, especially at high titers required for direct use in vivo, and further challenges are presented by the process of translating preclinical gene therapies toward manufacture of products for clinical investigation. The goals of this paper are to report the protocol for manufacturing high-titer third-generation lentivirus for preclinical testing and to provide detailed information on considerations for translating preclinical viral vector manufacture toward scaled-up platforms and processes in order to make gene therapies under Good Manufacturing Practice that are suitable for clinical trials.
No takes yet. Share an insight, caveat, or question.
Gándara et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: